KEYNOTE-355: Final results from a randomized, doubleblind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Simple item page
dc.contributor.authorCortés Castán, Javier
dc.contributor.authorCescon, D. W.
dc.contributor.authorRugo, H. S.
dc.contributor.authorIm, S. A.
dc.contributor.authorYuso, M. Md.
dc.contributor.authorGallardo, C.
dc.contributor.authorLipatov, O.
dc.contributor.authorBarrios, C. H.
dc.contributor.authorPérez García, José Manuel
dc.contributor.authorSchmid, P.
dc.contributor.authorEt al.
dc.date.accessioned2022-06-29T17:03:43Z
dc.date.available2022-06-29T17:03:43Z
dc.date.issued2021
dc.description.filiationUEMspa
dc.description.impact51.769 JCR (2021) Q1, 2/245 Oncologyspa
dc.description.impact8.590 SJR (2021) Q1, 2/133 Hematologyspa
dc.description.impactNo data IDR 2021spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationCortés, J., Cescon, D. W., Rugo, H. S., Im, S.-A., Md Yusof, M., Gallardo, C., Lipatov, O., Barrios, C. H., Perez-Garcia, J., Iwata, H., Masuda, N., Torregroza Otero, M., Gokmen, E., Loi, S., Guo, Z., Zhou, X., Karantza, V., Pan, W., & Schmid, P. (2021). KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Annals of Oncology, 32, S1289–S1290. https://doi.org/10.1016/j.annonc.2021.08.2089spa
dc.identifier.doi10.1016/j.annonc.2021.08.2089
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttp://hdl.handle.net/11268/11407
dc.language.isoengspa
dc.peerreviewedSispa
dc.relation.publisherversionhttps://doi.org/10.1016/j.annonc.2021.08.2089spa
dc.rights.accessRightsopen accessspa
dc.subject.otherNeoplasias de la mama triple negativasspa
dc.subject.otherQuimioterapiaspa
dc.subject.otherPlacebosspa
dc.subject.unescoCáncerspa
dc.subject.unescoTratamiento médicospa
dc.subject.unescoEfectos fisiológicosspa
dc.titleKEYNOTE-355: Final results from a randomized, doubleblind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBCspa
dc.typeconference outputspa
dspace.entity.typePublication
relation.isAuthorOfPublicationd8744cdc-311f-4ac5-afd5-fd6a05d6adc8
relation.isAuthorOfPublication.latestForDiscoveryd8744cdc-311f-4ac5-afd5-fd6a05d6adc8

Files

Collections

Otras Áreas de Investigación de Salud